Acadia Pharmaceuticals (ACAD) announced that the company has submitted a marketing authorization application to the European Medicines Agency for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union. Trofinetide is already approved in the United States and Canada for Rett syndrome in adults and pediatric patients two years of age and older.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Biotech Alert: Searches spiking for these stocks today
- Block upgraded, Bumble downgraded: Wall Street’s top analyst calls
- Guggenheim downgrades Acadia Pharmaceuticals to Neutral on lack of catalysts
- Acadia Pharmaceuticals downgraded to Neutral from Buy at Guggenheim
- CompoSecure to spin off Resolute, EHang raises Q4 revenue view; Morning Buzz